Sarepta Therapeutics, Inc. $SRPT
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING0
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO80%
Delay Index: of 5 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +15.9 months). See all sponsors →
Open Sarepta Therapeutics, Inc. on the live radar map → 📅 $SRPT readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| EMERGENE NCT06246513 |
P3 | Active, not recruiting | Limb-girdle Muscular Dystrophy | 17 | 2025-03-04 (+1 mo) |
| SRP-1003 IV Infusion NCT06138743 |
P1/2 | Enrolling by invitation | Myotonic Dystrophy 1 | 78 | 2026-12-31 (+15 mo) |
| ENVISION NCT05881408 |
P3 | Active, not recruiting | Duchenne Muscular Dystrophy | 148 | 2027-05-31 (+16 mo) |
| SRP-1001 for Injection NCT06131983 |
P1/2 | Enrolling by invitation | Muscular Dystrophy, Facioscapulohumeral | 60 | 2028-12-31 (+45 mo) |
| EXPEDITION NCT05967351 |
P3 | Enrolling by invitation | Duchenne Muscular Dystrophy | 400 | 2033-10-31 (+35 mo) |